Anergis SA

Transitioning its current interests in anti-allergy immunotherapy products into a broader R&D effort, UK-headquartered Allergy Therapeutics plc has extended its tie-up with two European biotechs, S

Two Swiss biotechs, Anergis SA and Virometix AG , are to join forces on the development of “ultra-fast” allergy immunotherapies, using Anergis’s expertise in allergy R&D and Virometix’s ability to

The progression of investigational products through a series of increasingly more sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for c

The progression of investigational products through a series of increasingly sophisticated and targeted clinical trials is a well-tried and tested route for the development of new medicines for commer